ArticlePloS one2025
Anticancer properties of peptides and protein hydrolysates derived from Asian water monitor (Varanus salvator) serum.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the anticancer efficacy of <3 kDa fractions derived from native peptides and protein hydrolysate of Varanus saltator serum. The inhibitory effects of these fractions were evaluated against a panel of cancer cell lines (A375, CaCO2, CAL27, NCI-H460, HeLa, HCT8, HT29, HepG2, KATO III, MCF-7, MDA-MB-231, Raw264.7, SKOV-3, SW620, T47D, and U937) and normal cell lines (HaCaT, MRC5, and Vero). Native peptides demonstrated higher anticancer activity compared to protein hydrolysates, inhibiting 16 cell lines and exhibiting high efficacy (≥70% inhibition) against CaCO2, CAL27, HaCaT, HT29, HepG2, MCF-7, MRC5, and U937. These native peptides were further fractionated by stepwise reverse-phase column chromatography. The hydrophilic (C18 unbound) peptide fraction exhibited greater anticancer activity than the hydrophobic (C18 bound) fraction. In addition, by LC-MS analysis, the peptide sequences were screening in silico. The predictions showed that 159 of the 432 Varanus peptides had the potential to be anticancer peptides (ACPs), of which the top twenty had a probability of more than 75%. The anticancer mechanism of peptides may be explained by the mechanism of cell entry or action. Further peptide synthesis and modification should be the next step to enhance the anticancer efficacy of these peptides with less toxicity to Vero cells. This finding sets the way for the development of new anticancer drugs originating from Varanus salvator serum peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.